Cadila Pharmaceuticals launches Bilacad Dex Syrup
A triple-action Formula for comprehensive respiratory relief
A triple-action Formula for comprehensive respiratory relief
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Star Health Insurance is modernising its claims ecosystem to be future-ready
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Globally, BRUKINSA is approved in more than 70 countries
33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley
Subscribe To Our Newsletter & Stay Updated